Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer risk: A population-based, case-control study

Annals of Internal Medicine

Volumn 163, Issue 5, 2015, Pages 347-355

  Friis, Søren ^a   Riis, Anders H ^b   Erichsen, Rune ^b   Baron, John A ^c   Sørensen, Henrik T ^b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; ASCENDING COLON; CANCER LOCALIZATION; CANCER PATIENT; CANCER RISK; COLONOSCOPY; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; DESCENDING COLON; DRUG MEGADOSE; DRUG USE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; POPULATION DYNAMICS; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT DURATION; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; DENMARK; DRUG ADMINISTRATION; INCIDENCE; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DENMARK; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; MALE; RISK FACTORS;

EID: 84940481188     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-0039     Document Type: Article

References (56)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136: E359-86. [PMID: 25220842] doi:10.1002/ijc.29210
2. Northover JMA, Arnott S, Jass JR, Williams NS. Colorectal cancer. In: Souhami RL, Tannock I, Hohenberger P, Horiot JC, eds. Oxford Textbook of Oncology. 2nd ed. New York: Oxford Univ Pr; 2012: 1545-89.
3. Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol. 2005;23:378-91. [PMID: 15637400]
4. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology. 2010;138:2029-2043.e10. [PMID: 20420944] doi:10.1053/j.gastro.2010.01.057
5. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5:164-78. [PMID: 22084361] doi:10.1158/1940-6207.CAPR-11-0391
6. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518-27. [PMID: 22440112] doi:10.1016/S1470-2045(12)70112-2
7. Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. 2015;26:47-57. [PMID: 25096604] doi:10.1093/annonc/mdu225
8. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60. [PMID: 19482214] doi:10.1016/S0140-6736(09)60503-1
9. Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut. 2010;59:1670-9. [PMID: 20844293] doi:10.1136/gut.2009.203000
10. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23:1403-15. [PMID: 22517822] doi:10.1093/annonc/mds113
11. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101: 256-66. [PMID: 19211452] doi:10.1093/jnci/djn485
12. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741-50. [PMID: 20970847] doi:10.1016/S0140-6736(10)61543-7
13. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012; 379:1602-12. [PMID: 22440946] doi:10.1016/S0140-6736(11)61720-0
14. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternateday, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159:77-85. [PMID: 23856681] doi:10.7326/0003-4819-159-2-201307160-00002
15. Ishikawa H, Mutoh M, Suzuki S, Tokudome S, Saida Y, Abe T, et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut. 2014;63:1755-9. [PMID: 24488498] doi:10.1136/gutjnl-2013-305827
16. Mahipal A, Anderson KE, Limburg PJ, Folsom AR. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev. 2006;15:1785-90. [PMID: 17035383]
17. Hoffmeister M, Chang-Claude J, Brenner H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. Int J Cancer. 2007;121:1325-30. [PMID: 17487832]
18. Huang WK, Chiou MJ, Yu KH, Lin YC, Yang TS, Chen JS, et al. The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study. Aliment Pharmacol Ther. 2013;38:432-9. [PMID: 23799975] doi:10.1111/apt.12388
19. Stürmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med. 1998;128:713-20. [PMID: 9556464]
20. García-Rodríguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology. 2001;12:88-93. [PMID: 11138826]
21. Friis S, Sørensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer. 2003; 88:684-8. [PMID: 12618874]
22. Allison M, Garland C, Chlebowski R, Criqui M, Langer R, Wu L, et al; Women's Health Initiative Investigators. The association between aspirin use and the incidence of colorectal cancer in women. Am J Epidemiol. 2006;164:567-75. [PMID: 16847042]
23. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008;134:21-8. [PMID: 18005960]
24. Hollestein LM, van Herk-Sukel MP, Ruiter R, de Vries E, Mathijssen RH, Wiemer EA, et al. Incident cancer risk after the start of aspirin use: results from a Dutch population-based cohort study of low dose aspirin users. Int J Cancer. 2014;135:157-65. [PMID: 24285345] doi:10.1002/ijc.28634
25. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, et al; APPROVe Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131:1674-82. [PMID: 17087947]
26. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al; APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873-84. [PMID: 16943400]
27. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, et al; PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885-95. [PMID: 16943401]
28. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10: 501-7. [PMID: 19410194] doi:10.1016/S1470-2045(09)70035-X
29. Fischer SM, Hawk ET, Lubet RA. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila). 2011;4:1728-35. [PMID: 21778329] doi: 10.1158/1940-6207.CAPR-11-0166
30. Sahin IH, Hassan MM, Garrett CR. Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: current state-of-the science. Cancer Lett. 2014;345:249-57. [PMID: 24021750] doi:10.1016/j.canlet.2013.09.001
31. Ehrenstein V, Antonsen S, Pedersen L. Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol. 2010;2:273-9. [PMID: 21152254] doi:10.2147/CLEP.S13458
32. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry - history, content, quality and use. Dan Med Bull. 1997;44:535-9. [PMID: 9408738]
33. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011;39:42-5. [PMID: 21775350] doi:10.1177/1403494810393562
34. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39:30-3. [PMID: 21775347] doi:10.1177/1403494811401482
35. Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39:22-5. [PMID: 21775345] doi:10.1177/1403494810387965
36. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29: 541-9. [PMID: 24965263] doi:10.1007/s10654-014-9930-3
37. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
38. Schmidt M, Hallas J, Friis S. Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999-2012. Clin Epidemiol. 2014;6:155-68. [PMID: 24872722] doi:10.2147/CLEP.S59156
39. Jørgensen TL, Herrstedt J, Friis S, Hallas J. Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006. J Geriatr Oncol. 2012;3:33-40.
40. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo, Norway: World Health Organization; 2013. Accessed at www.whocc.no/atc-ddd-index on 25 June 2015.
41. Flanders WD, Louv WC. The exposure odds ratio in nested case-control studies with competing risks. Am J Epidemiol. 1986;124:684-92. [PMID: 3752062]
42. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
43. Ostenfeld EB, Frøslev T, Friis S, Gandrup P, Madsen MR, Søgaard M. Completeness of colon and rectal cancer staging in the Danish Cancer Registry, 2004-2009. Clin Epidemiol. 2012;4 Suppl 2:33-8. [PMID: 23115791]
44. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-20. [PMID: 14585769]
45. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005; 294:47-55. [PMID: 15998890]
46. Friedman GD, Coates AO, Potter JD, Slattery ML. Drugs and colon cancer. Pharmacoepidemiol Drug Saf. 1998;7:99-106. [PMID: 15073733]
47. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-9. [PMID: 12621133]
48. Wallace K, Grau MV, Ahnen D, Snover DC, Robertson DJ, Mahnke D, et al. The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum. Cancer Epidemiol Biomarkers Prev. 2009;18:2310-7. [PMID: 19661090] doi:10.1158/1055-9965.EPI-09-0211
49. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev. 2011;33:88-100. [PMID: 21633092] doi:10.1093/epirev/mxr004
50. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al; UK Flexible Sigmoidoscopy Trial Investigators. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375:1624-33. [PMID: 20430429] doi:10.1016/S0140-6736(10)60551-X
51. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al; Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769-79. [PMID: 23726390] doi:10.1016/S0140-6736(13)60900-9
52. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9:259-67. [PMID: 22473097] doi:10.1038/nrclinonc.2011.199
53. Wang D, DuBois RN. The role of anti-inflammatory drugs in colorectal cancer. Annu Rev Med. 2013;64:131-44. [PMID: 23020877] doi:10.1146/annurev-med-112211-154330
54. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11: 83. [PMID: 21619668] doi:10.1186/1471-2288-11-83
55. Andersen FH. [Colonoscopies performed as surgical outclinic procedures]. Ugeskr Laeger. 2007;169:514-7. [PMID: 17303033]
56. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013;22:559-70. [PMID: 23616423]